The U.S. Supreme Court justices on Monday seemed confused as they grappled for more than an hour and a half over how many antibodies are actually covered by Amgen patents underlying the cholesterol drug Repatha, and how much experimentation it would take to reach the patents' full scope.
The U.S. Supreme Court justices on Monday seemed confused as they grappled for more than an hour and a half over how many antibodies are actually covered by Amgen patents underlying the cholesterol drug Repatha, and how much experimentation it would take to reach the patents' full scope.
The lone patent case the U.S. Supreme Court has agreed to hear this term centers on how pharmaceutical companies claim antibodies in patents and the way that impacts competing cholesterol medications, meaning a decision will clearly have implications for attorneys in the life sciences area. But lawyers who focus on software and other sectors should be paying attention as well.
A Federal Circuit judge on Friday told colleagues that there "ought to be a way" to make software patents eligible again, as part of a larger discussion on the frustrating state of patent eligibility law and what role they can play in helping it.
The U.S. Supreme Court on Monday will look into what the standard should be for patents to be enabled, in a dispute pitting major players in the pharmaceutical industry against each other. Here's what you need to know about the case.